SOCTEC
LIVE

Serial Number

86364754

Owner

SKYEPHARMA PRODUCTION S.A.S.

Attorney

Molly Buck Richard

Filing Date

Aug 12, 2014

Add to watchlist:

No watchlists yet
View on USPTO

SOCTEC Trademark

Serial Number: 86364754 • Registration: 5494819

SOCTEC is a trademark filed by SKYEPHARMA PRODUCTION S.A.S. on August 12, 2014. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

SKYEPHARMA PRODUCTION S.A.S.

55 RUE DU MONTMURIER 38070
SAINT-QUENTIN-FALLAVIER , FR

Entity Type: 99

JAGOTEC AG (32 trademarks)

POSTFACH 244
HERGISWIL NW , CH

Entity Type: 03

Trademark Details

Filing Date

August 12, 2014

Registration Date

June 19, 2018

Published for Opposition

April 3, 2018

Goods & Services

[ Pharmaceuticals having a self-orienting effect, namely, orally delivered pharmaceuticals with modified time release into the gastrointestinal system; gastro retentive pharmaceuticals; self orienting pharmaceuticals in the form of capsules, namely, capsules consisting of segments of varied functions and absorption rates, resulting in controlled release into the gastrointestinal tract; Gastrointestinal drug delivery preparations for medical, surgical and biological purposes; chronotherapy-focused tablets, analgesics; Medicines for treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; medicinal preparations for treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; capsules for the release of colonic drug delivery; pharmaceuticals for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders, medical and veterinary preparations for body slimming purposes; capsules, suppositories, tablets and pills for pharmaceutical, medical and veterinary purposes for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pre-filled vials containing medical diagnostic reagents; exclude goods being related to the treatment of respiratory diseases ]

[ Medical services; veterinary services; hygienic care for human beings or animals; medical analysis for the diagnosis and treatment of persons treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmacy advice; provision of information relating to medical, surgical and veterinary matters online from a computer database or over the Internet; exclude services in the field of inhalation technology ]

[ inhalers for medical purposes; injection apparatus, instruments and devices, namely, medical apparatus in the nature of an infusion injection device for administering drugs; apparatus, instruments and devices, namely, automated drug delivery systems for storing and dispensing medical, surgical and veterinary preparations, capsules, powders, tablets and pills; instruments and apparatus for the administration of self-orientation therapy and prophylaxis preparations and substances, namely, gastrointestinal drug delivery systems, syringes and fluid injectors for medical purposes; exclude goods being related to the treatment of respiratory diseases ]

Scientific and technological services, namely, custom design exclusively in the pharmaceuticals and medical fields; design services exclusively in the pharmaceuticals and medical fields; drug development and custom design of pharmaceuticals and medical goods; exclude services in the field of inhalation technology

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 22, 2025 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 22, 2025 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 21, 2025 APRE
TEAS SECTION 8 & 15 RECEIVED
Aug 29, 2024 E815
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 22, 2024 ASGN
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 19, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Jun 19, 2018 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 29, 2018 TCCA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 3, 2018 NPUB
PUBLISHED FOR OPPOSITION
Apr 3, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 14, 2018 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 26, 2018 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 13, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 13, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 12, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 12, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 12, 2018 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 27, 2017 GNRN
NON-FINAL ACTION E-MAILED
Nov 27, 2017 GNRT
NON-FINAL ACTION WRITTEN
Nov 27, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2017 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 2, 2017 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 31, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 31, 2017 GNSL
SUSPENSION LETTER WRITTEN
Oct 31, 2017 CNSL
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 31, 2017 ZZZX
CASE RETURNED TO EXAMINATION
Oct 31, 2017 OTHE
NOTICE OF ALLOWANCE CANCELLED
Oct 31, 2017 IUCN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 9, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 14, 2017 NPUB
PUBLISHED FOR OPPOSITION
Mar 14, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 22, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 7, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 31, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 31, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 31, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 31, 2017 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Aug 15, 2016 GPRN
PRIORITY ACTION E-MAILED
Aug 15, 2016 GPRA
PRIORITY ACTION WRITTEN
Aug 15, 2016 CPRA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 20, 2016 RCCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 14, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 14, 2016 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 14, 2016 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 20, 2016 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 20, 2016 GNSL
SUSPENSION LETTER WRITTEN
Jan 20, 2016 CNSL
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 29, 2015 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 25, 2015 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 25, 2015 GNSL
SUSPENSION LETTER WRITTEN
Jun 25, 2015 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 8, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 8, 2015 CRFA
ASSIGNED TO LIE
Jun 1, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 26, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 26, 2014 GNRN
NON-FINAL ACTION E-MAILED
Nov 26, 2014 GNRT
NON-FINAL ACTION WRITTEN
Nov 26, 2014 CNRT
ASSIGNED TO EXAMINER
Nov 25, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 21, 2014 NWOS
NEW APPLICATION ENTERED
Aug 15, 2014 NWAP